The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in ...

Frazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by ...

Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit ...

A few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change ...

Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the ...

The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is ...

The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation ...

Newly solidified in their roles as the heads of CBER and CDER, Karim Mikahil and Michael Davis have been working for months ...

Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for ...

Encoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial ...

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment ...

With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial ...